+ macrophage production of IL-23 and IL-1b. This suppression was contact dependent and was mediated by latent activation gene-3 (LAG-3)-an immune checkpoint receptor-expressed on Treg cells. Engagement of LAG-3 on MHC class II drove profound immunosuppression of CX3CR1 + tissue-resident macrophages. Our study reveals that the health of the intestinal mucosa is maintained by an axis driven by Treg cells communication with resident macrophages that withhold inflammatory stimuli required for ILC3 function.
In Brief
Treg cells control of tissue resident macrophages and ILC3 function has not been elucidated. + Treg cells suppress the production of proinflammatory cytokines by CX3CR1 + macrophages and thereby inhibit ILC3-driven colitis.
INTRODUCTION
Defects in mucosal immune tolerance can lead to inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. These syndromes are marked by unrestrained gastrointestinal inflammation leading to damage of mucosal barrier surfaces. In the United States alone there are more than 1.4 million IBD patients with 70,000 new cases diagnosed annually (Lakatos, 2006; Loftus, 2004) . The root cause remains enigmatic; but host genetics, perturbations in intestinal flora, overuse of antibiotics, hormone regulation, and chronic immune activation are all implicated in disease development. Indeed, the major IBD susceptibility genes, which include NOD2, STAT3, and interleukin-23 (IL-23) (Barrett et al., 2008; Duerr et al., 2006) , are closely associated with immune activation. It is now well recognized that IL-23 can drive a number of tissue repair mechanisms and host defense pathways including production of interleukin-22 (IL-22) and interleukin-17 (IL-17) from innate and adaptive cells in the intestinal tract (Ouyang et al., 2008) . Fittingly, IL-23, IL-17, and IL-22 concentration are all elevated in the serum and intestine of IBD patients (Brand et al., 2006; Fujino et al., 2003; Glas et al., 2011) . Although the role of IL-17 and IL-23 in inflammatory diseases is known, the role of IL-22 is controversial. Indeed, murine models have revealed crucial roles for IL-22 in the regulation of intestinal barrier surfaces through the induction of epithelial cell proliferation, goblet cell regeneration, and antimicrobial peptide expression (Parks et al., 2016) . A growing number of studies have identified IL-22 as a double-edged sword cytokine involved in intestinal integrity maintenance and pathogenicity (Eken et al., 2014; Zenewicz et al., 2008) . In the gut, IL-22 is mainly expressed by group 3 innate lymphoid cells (ILC3) and produced at lower amount by CD4 + T cells (Sonnenberg et al., 2011) . Expression of IL-22 in ILC3 is tightly regulated by gut microbiota, food-derived metabolites, cytokines, and transcription factors such as RORgt, STAT3, and AhR (Kiss and Diefenbach, 2012) . Pro-inflammatory cytokines such as IL-23 and IL-1b that enhance IL-22 production, as well as GM-CSF, are mainly produced by tissue-resident CX3CR1 + macrophages and to some extent by CD103 + CD11b + dendritic cells (Kinnebrew et al., 2012; Longman et al., 2014; Mortha et al., 2014) . In response to Toll-like receptor (TLR) stimulation, CX3CR1 + macrophages (also described as myeloid dendritic cells or mononuclear phagocytes) are an important source of IL-23 and specific deletion of these cells results in decreased proportion of IL-22-producing ILC3 (Longman et al., 2014; Manta et al., 2013; Satoh-Takayama et al., 2014) .
Foxp3-expressing regulatory T cells (Treg cells) play a crucial role in intestinal homeostasis. Mice lacking Treg cells or Treg cell function are more prone to spontaneous colitis and T cells induced colitis (Chaudhry et al., 2011; Josefowicz et al., 2012; Rubtsov et al., 2008) . Treg cells are capable of inhibiting T cell activation and proliferation through various mechanisms such as the secretion of immunosuppressive cytokines , metabolic disruption and regulation of antigen-presenting myeloid cells (Vignali et al., 2008) . A recent study reported that adoptive transfer of Treg cells into Rag2 À/À mice suppress anti-CD40 mediated colitis (Kim et al., 2013) , an acute model driven by IL-22-producing ILC3. This report along with another study by Powrie and coworkers suggest that Treg cells could suppress innate cells during colitis. However the mechanism underlying this suppression remains unclear (Maloy et al., 2003) .
Here we show that passive transfer of Foxp3 + Treg cells suppressed ILC3-driven colitis. Moreover, ablation of Treg cells using Foxp3DTR mice led to an upregulation of IL-22-producing ILC3 during the early phase of colitis. Furthermore, Treg cells directly repressed CD40 and NF-kB signaling in CX3CR1 + macrophages but not CD103 + DC, leading to a decreased expression of the pro-inflammatory cytokines IL-23 and IL-1b. Finally, we demonstrated that LAG-3 expression on Treg cells was required to fully suppress CX3CR1 + macrophages. Our study provides a clear demonstration that colonic tissue resident ILC3 can play a pathogenic role. In addition, Treg cells can suppress the inflammatory activities of CX3CR1 + macrophage and indirectly through ILC3, to maintain tissue homeostasis.
RESULTS

Regulatory T Cells Prevent IL-22 Producing ILC3-Mediated Colitis
While T cells can interact with dendritic cells to initiate an immune response to self-antigens and ''commensal bacterial'' antigens, ILC3 are tissue-resident cells expressing innate stress sensors, allowing them to respond rapidly to tissue injury by producing protective cytokines. When dysregulated, ILC3 drive acute inflammation and therefore lead to tissue damage in the anti-CD40 colitis model (Buonocore et al., 2010; Eken et al., 2014; Vonarbourg et al., 2010 ; see Figure S1 ). As previously reported, IL-22 but not IL-17A-producing ILC3, drive intestinal inflammation in the anti-CD40 colitis model in Rag2 À/À mice (Figure S1, data not shown; Eken et al., 2014) . Studies demonstrated that Treg cells can suppress innate cell-driven colitis in anti-CD40 (Kim et al., 2013) and Il10 À/À Helicobacter models (Maloy et al., 2003) . However, the mechanisms by which Treg cells control innate cell activation during early phase of colitis is unclear. Figures 1A-1C) . Notably, circulating IL-22 was clearly reduced in the Treg cell transfer group compared to the controls, suggesting that Treg cells can suppress ILC3 production of IL-22 ( Figure 1D ). Gene-expression analysis of colonic tissues showed that mice receiving Treg cells had reduced expression of intestinal inflammatory cytokines such as Il1b, Il6, Tnfa, and defensin genes, which are associated with ILC3-dependent tissue injury responses ( Figure 1E ). Moreover, we observed a significantly decreased proportion of IL22-producing ILC3 in the colon lamina propria of mice receiving Treg cells ( Figures 1F-1G and Figure S1C ). We next determined whether Treg cell could suppress IL-22 producing ILC3 in T cell-sufficient mice. We chose two models, the anti-CD40 colitis model where IL-22-expressing ILC3 are pathogenic (Buonocore et al., 2010; Eken et al., 2014) and the Citrobacter rodentium model where protective IL-22 produced by ILC3 is required to clear bacteria during first week of infection (Silberger et al., 2017) . We depleted Treg cells in Foxp3-DTR mice and analyzed colons 3-4 days after induction of colitis in both models (Figure 2A ). Depletion of Treg cells led to an increased concentration of IL-23 and production of IL-22 by colonic ILC3 in both the Citrobacter rodentium ( Figures 2B-2D ) and the anti-CD40 colitis model ( Figures 2H and 2I) . The consequence of the IL-22 up-regulation after Treg cell depletion reduced bacterial dissemination in Citrobacter rodentium model ( Figure 2E ) is increased colon pathology during anti-CD40 mediated colitis (Figures 2F and 2G) . Altogether these results demonstrate that Treg cells can suppress immune activation of ILC3.
Regulatory T Cells Inhibit Production of IL-23 and IL-1b by CX3CR1
+ Macrophages but Not CD103 + DC
We have demonstrated that Treg cells can inhibit innate cell activation in RAG-deficient and C57BL/6 mice. To assess the cellular mechanism of suppression, we co-cultured Treg cells with total colonic lamina propria cells (isolated from Rag2 À/À mice) and measured the secreted cytokines. Treg cells suppressed lamina propria myeloid cell-produced cytokines such as IL-1b, IL-23, TNF, and MCP1, as well as lymphoid cell-produced IL-22 and GM-CSF. In contrast, co-culture of colonic lamina propria with effector CD4 + T cells enhanced IL-2, IL-22, and GMCSF production ( Figure S2 ). These data suggest that Treg cells could modulate cytokine production by myeloid cells. Previous reports identified CX3CR1-expressing tissue resident macrophage and CD103 + DC as major producers of IL23 and IL-1b, which are potent factors enhancing production of IL-22 (Kinnebrew et al., 2012; Longman et al., 2014; Satoh-Takayama et al., 2014 Figure S3C ). Although required for Citrobacter rodentium clearance (Aychek et al., 2015; Longman et al., 2014; Manta et al., 2013) ,the role of CX3CR1 + macrophages in the anti-CD40 mediated colitis model has not been studied. We showed that depletion of CX3CR1 + macrophages, via infusion of anti-CSF1R lytic antibody (Koscsó et al., 2016) significantly decreased concentration of the circulating IL-23 and reduced the number of colonic IL-22-producing ILC3 and subsequently attenuated anti-CD40-driven colitis Figure 3F , Figures S4C and S4D , data not shown).
As a consequence, intestinal ILC3 produced less IL-22 when cultured with the supernatant from co-culture of CX3CR1 + macrophages and activated Treg cells ( Figure 3G Contact and Antigen Dependent CX3CR1 + macrophages are localized in the lamina propria close to the epithelium where they extend their dendrite processes through the tight junction of the epithelium to sense the microbiota (Niess et al., 2005) . Here the microbial antigens and metabolites are consistently processed and presented to conventional CD4 + T cells, intraepithelial cells (Chang et al., 2013; Rossini et al., 2014) required to promote cytokine production, we co-cultured OTII-expressing Treg cells with OVA peptide-pulsed CX3CR1 + macrophages and measured IL-23 and IL-1b production by ELISA. We showed that OTII Treg cells were capable of inhibiting IL-23 and IL-1b production in CX3CR1 + macrophages only when CX3CR1 + cells were pulsed with OVA peptide ( Figure 5F ). Recent studies demonstrated that most of the colonic ILC3 are able to process and present antigens in an MHCII-dependent manner (Hepworth et al., 2015; Hepworth et al., 2013 ). Because we also observed close contact between Treg cells and ILC3 after transfer into Rag2 À/À mice ( Figure S6A ), we considered whether Treg cells could directly inhibit IL-22 production by ILC3 after antigen presentation. Therefore, we co-cultured OVA peptide-pulsed ILC3 with OTIIexpressing Treg cells. We found that Treg cells did not inhibit IL-22 production in ILC3 both in presence or absence of OVA peptide ( Figures S6B and S6C ). Our data demonstrate that Treg cells inhibit IL-23 and IL-1b production in CX3CR1 + macrophages in a contact and antigen dependent manner but indirectly regulate ILC3 production of IL-22 via suppression of IL-23 in the macrophages.
Treg Cell-Mediated CX3CR1 + Macrophage Inhibition Is LAG-3 Dependent Our data suggest that TCR engagement on Treg cells is required to fully inhibit cytokine production by CX3CR1 + macrophages.
Phenotypic analysis of anti-CD3+anti-CD28 activated Treg cells revealed that upon TCR stimulation, Treg cells expressed more cell surface LAG-3 and ICOS, at both the mRNA and protein level (Figures 6A and 6B) . These molecules are recognized as immune checkpoints which regulate T cell activation (Huang et al., 2004; Pardoll, 2012) . In contrast, activated Treg cells did not increase expression of Pd1, Cd40l, Cd39, Cd73, or Tigit genes ( Figure 6B ).
To evaluate whether Treg cell suppression of colitis in the anti-CD40 IBD model is ICOS and/or LAG-3-dependent, we transferred Treg cells into Rag2 À/À mice and treated the recipients with neutralizing anti-CTLA4, anti-TIM3, anti-ICOS, or anti-LAG-3 mAbs before induction of colitis. We found that only mice receiving the anti-LAG-3 treatment developed severe colitis comparable to Rag2 À/À mice without Treg cells as assessed by histopathology score 7 days after induction of colitis ( Figures  6C and 6D ). Although Ctla4 and Tim3 expression was also higher, these molecules were not required for Treg cell-mediated suppression of anti-CD40-driven colitis (data not shown).
We further confirmed in vitro that Treg cell-mediated IL-23 and IL-1b inhibition in CX3CR1 + cells was LAG-3-dependent and ICOS-independent ( Figure 6E ). LAG-3 has been shown to be expressed by a broad range of cell types including T cells, NK cells, and plasmacytoid dendritic cells (Anderson et al., 2016; Castelli et al., 2014 6G ) and the expression of inflammatory cytokines in the colon ( Figure 6H , Figure S7 ). Altogether, our data demonstrate that LAG-3 expression on Treg cells is required to suppress ILC3-dependent colitis.
LAG-3 Signaling Is Not Required for Treg Cell Survival
To assess the role of LAG-3 signaling in Cd40l, Ctla4, Icos, Gitr, Tim3, and Il10 and downregulate Cd39, Pd1, Cd73, Tigit, Tgfbr2, and Foxp3 (Figure 7A) . Previous studies have reported that LAG-3-expressing Treg cells secrete high amount of IL-10 and TGF-b (Camisaschi et al., 2010) , two cytokines capable of suppressing innate-driven colitis (Maloy et al., 2003) . Here we showed that LAG-3-deficiency per se did not impair TGF-b and IL-10 expression ( Figures 7A and 7B ). Moreover, none of these cytokines were required for suppression of anti-CD40-driven colitis ( Figure 7C , data not shown). We next determined whether LAG-3-deficiency could influence Treg cell proliferation and survival 6 days after adoptive transfer to Rag2 À/À hosts. Here we did not find any difference in the proliferation and apoptosis markers in WT and Lag3 À/À Treg cells isolated from the spleen of the donor mice ( Figures S8A and S8B ). In addition, both WT and Lag3 À/À Treg cells isolated from the colon of recipient mice also showed similar proliferation and survival ( Figure S8C ).
Recombinant LAG-3 Suppress IL-1b and IL-23p19 Expression in CX3CR1 + Macrophages in a MHC Class II-
Dependent Manner
Our data suggest that engagement of LAG-3 to a cell-surface receptor on CX3CR1 + macrophages could suppress their function. Two possible LAG3 receptors on tissue-resident macrophages include MHCII and Galectin-3 (Andreae et al., 2003; Hemon et al., 2011; Kouo et al., 2015) . To determine which of these cell surface receptors might regulate activation of intestinal CX3CR1 + cells, we isolated gut macrophages from WT, MHCII-deficient, or Galectin-3-deficient mice and stimulated the cells with LPS in the presence of recombinant LAG-3-Fc. We found that LAG-3-Fc can suppress multiple inflammatory genes including Il1b, Il23a, Cd80, and Nrpl3 in an MHCII-dependent manner. In contrast, the presence or absence of Galectin-3 did not influence LAG-3-mediated effects ( Figure 7D ). These data suggest that LAG-3 binding to MHC class II molecule specifically suppresses the expression of pro-inflammatory cytokines in CX3CR1 + macrophages. Thus, there is remarkable symmetry that LAG-3 engagement of MHC-II promotes immune tolerance by simultaneously suppressing adoptive T cell immunity and preventing immune activation of tissue-resident macrophages.
DISCUSSION
Maintaining balance in mucosal tissues requires a complex network involving environmental sensors, the presence of commensal microbes, and crosstalk between adaptive and innate cells to activate or attenuate immune responses. ILCs and myeloid cells constitute two major classes of innate sentinels residing in gut-associated tissues. In our study, the anti-CD40 IBD model is primarily limited to the proximal colon; therefore, we focused on the ILC3 isolated from the colonic lamina propria. As previously demonstrated, IL-22-producing ILC3 are key players in the anti-CD40 colitis model (Eken et al., 2014; Pearson et al., 2016) . Extensive literature demonstrates the protective role of IL-22 during colitis (Li et al., 2014; Sugimoto et al., 2008; Zenewicz et al., 2008) ; however, the pathogenic role of IL-22 during innate cell-induced colitis remains to be determined. In the colon lamina propria, ILC3 are clustered close to the base of the crypt, where stem cells reside (Aparicio-Domingo et al., 2015; Pearson et al., 2016 close to the epithelium where they can sense lumen-derived antigens (Niess et al., 2005) and present antigens to conventional CD4 + T cells and gut-resident T cells (Chang et al., 2013; Rossini et al., 2014) . We showed that antigen presentation by CX3CR1 + macrophages was required to activate Treg cells in vitro. However, the role of CX3CR1 + macrophages as antigen-presenting cells is still controversial. Some studies have demonstrated that this subset can take up antigen and activate gut-resident T cells (Rossini et al., 2014; Chang et al., 2013) whereas others demonstrated that CX3CR1 + macrophages pass antigen to CD103 + DC (Mazzini et al., 2014 Treg cell differentiation from naïve T cells in a TGF-b and retinoic-aciddependent manner (Coombes et al., 2007; Schulz et al., 2009) . We believe that crosstalk between CX3CR1 + and CD103 + DCs is required for ''long-term'' adaptive immunity, whereas activation of T cells by CX3CR1 + macrophages is important during the acute phase of inflammation. Our data suggests that Treg cell activation by CX3CR1 + macrophages occurs in the lamina propria, raising the question of the nature of the antigen being presented.
We show that suppression of CX3CR1 + macrophages by Treg cells is LAG-3-dependent. LAG-3, a ligand for MHC class II and Galectin-3, two molecules expressed by CX3CR1 + macrophages (Kouo et al., 2015; Liang et al., 2008; Shan et al., 2013) , is over-expressed in activated Treg cells and colonic Treg cells (Sefik et al., 2015) . Crosslinking LAG-3 to MHC class II reduces antigen presentation to conventional T cells (Liang et al., 2008) but little is known about MHC class II signaling pathway activation or repression in myeloid cells upon LAG-3 binding. We show that ligation of LAG-3 on colonic CX3CR1 + macrophages sends a negative signal and downregulate Il23a and II1b production in the context of LPS stimulation. However, further studies are required to decipher the molecule mechanism controlling this inhibitory LAG3-MHC class II signaling pathway. LAG-3 is a CD4-like molecule that binds MHC class with a greater affinity than CD4 (Andrews et al., 2017) . Whereas CD4 binds MHC class II interaction in the presence of antigen, whether LAG-3 binding to MHC class II required antigen presentation remain elusive. Soluble recombinant LAG-3 was shown to impair human myeloid cells in the absence of exogenous peptide . This suggests that peptide presentation by the MHC class II is not required for LAG-3 interaction with MHCII. In our study, we stimulated flow cytometry sorted intestinal CX3CR1 + macrophages with a recombinant LAG-3. Because of the gut origin of these cells and their capacity to uptake antigens, we cannot rule out that CX3CR1 + cells were loaded with gut luminal peptides. Liang et al. (2008) suggested that antigen presentation is required for LAG-3 function. However, in the absence of OVA peptide, OTII-expressing Treg cell cannot upregulate LAG-3 suggesting that antigen could only be required for Treg cell activation. LAG-3-expressing Treg cells (Foxp3 + or Foxp3 À ) were shown to produce IL-10 (Camisaschi et al., 2010), a cytokine involved in Treg cell-mediated suppression of immune pathology (Maloy et al., 2003) . IL-10 was shown to downregulate CD40 expression and IL-23 production by CX3CR1 + macrophages (Zigmond et al., 2014 ILCs. The study reveals that LAG-3 is a key immunosuppressive factor on Treg cells that constrains and limits tissue resident macrophages to initiate inflammation. While LAG-3 antagonists are currently being tested in the clinic as a cancer immunotherapy agent, our data suggest that activation of the LAG-3 pathway-either through enhancing Treg function or suppressing CX3CR1 + macrophages-could be an important therapeutic strategy for treatment of IBD patients.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Data representative of two to four independent experiments (n = 3-10 mice/ group). Please also see Figure S7 .
AUTHOR CONTRIBUTIONS STAR+METHODS
Bacterial and Virus Strains
Citrobacter rodentium strain DBS100 ATCC Cat# ATCC51459 Anti-CD40 IBD Mouse Model C57BL/6 Rag2 -/-and Foxp3GDL mice were used at 8-16 weeks of age. At day 0, mice were administered i.p with 100 mg of anti-CD40 (IgG2a, monoclonal Ab FGK45 from BioXCell) to induce IBD (Rolink et al., 1996) . The naïve group did not receive any treatment. Weight loss was measured relative to initial weight in all studies. Mice were sacrificed by carbon dioxide asphyxiation at day 2 or 7. Plasma was collected for ELISA and Luminex assays. Two cm of colon, proximal to the cecum, was collected and treated as follows: 1) fixed in 10% neutral buffered formalin and stained paraffin-embedded tissue sections with H&E to evaluate tissue pathology; 2) snap-frozen in liquid nitrogen for further RNA extraction; or 3) placed in ice-cold, calcium-, magnesium-and phenol red-free HBSS for separation of epithelial cells from lamina propria. Rag1 -/-and Rag1 -/-Cx3cr1-eGFP/eGFP mice were born and raised under germ-free conditions in sterile isolators, at the University of Bern animal facility. At the age of 7 weeks, mice were co-housed for 4 weeks with a female mouse colonized with the sDMDMm2 gnotobiotic microbiota consisting 12 defined bacterial strains (Brugiroux et al., 2016; Li et al., 2015) before induction of anti-CD40-mediated colitis.
Citrobacter Rodentium Foxp3DTR mice were orally gavaged with 10 10 colony-forming units (CFUs) Citrobacter rodentium strain DBS100 (ATCC). 4 days after infection, livers were harvested, weighted and plated on a macconkey agar (Sigma). nously to C57BL/6 Rag2 -/-and parked for 5 days followed by anti-CD40 treatment.
In Vivo
Antibody and Diptheria Toxin Treatment
Rag2 -/-mice were injected in i.p with 1mg of depleting anti-CSF1R mAb (BioXCell, clone AFS98) or isotype control (BioXCell, Rat IgG2a) 3 and 2 days prior anti-CD40 treatment and then 500ug of depleting antibody or control every 2 two days. Rag2 -/-were injected in i.p with either 500mg of anti-IL22 (RnD systems) at day -1 and day 2 post injection of anti-CD40 or 500mg of anti-LAG-3 (clone C9B7W, BioXCell), anti-ICOS (clone 7E.17G9,BioXCell) blocking antibodies or isotypes controls (rat IgG1, clone TN96A7 and Rat IgG2b, clone LTF2, BioXCell) 0,2 and 3 days prior anti-CD40 treatment.
Foxp3DTR mice were injected in i.p with 15mpk (about 300ng/mouse) of Diphteria toxin (Sigma) for three days in a row and every other days. 
Colon Lamina Propria Cell Isolation
Colon LP cells were isolated by first removing epithelial cells through the incubation of 0.5cm gut tissue pieces in Hank's buffered salt solution containing 5mM EDTA and 10cmM HEPES for 20min at 37c C and then repeating this incubation one additional time. The remaining tissue was cut into small fragments and then digested with complete RPMI medium containing 2mgml À1 Collagenase Type VIII (Sigma-Aldrich) and 30Uml À1 DNaseI (Sigma-Aldrich) at the same conditions. The resulting cell suspension was layered on to a 40%/80% Percoll gradient and centrifuged for 10min at 600g; LP cells were recovered at the interface. When cytokines productions was measured by flow cytometry, cells were stimulated with 500ng/ml Ionomycin and 50ng/ml PMA (Sigma) and Brefeldin A (BD bioscience) for 4 hours prior to staining.
For NFkb p65 phosphorylation (K10-895.12.50, BD) cells were stimulated with LPS, fixed with pre-warmed BD Fix buffer I (BD bioscience) for 10 minutes, permeabilized with pre-chilled BD Perm buffer III (BD bioscience) for 30 minutes and stained for 30 minutes on ice. Acquisition was performed on either LSR II flow cytometer (BD). Data were analyzed using FlowJo software (Tree Star)
In Vitro Assay All cells were cultured in IMDM medium with 10% (vol/vol) fetal bovine serum (Hyclone), 2 mM glutamine, 100 IU/ml of penicillin, 0.1 mg/ml of streptomycin and 20 mM HEPES buffer, pH 7.2-7.5 (all from Invitrogen) and 2 mM b-mercaptoethanol (Sigma-Aldrich). Purified Treg cells were stimulated with 1mg/mL CD3 (clone 145-2C11, BD) and 2mg/mL CD28 (clone 37.51, BD) for two hours prior to co-culture at a 1:10 ratio with cLP, sorted CX3CR1 Figure 3) then cells were restimulated with 500ng/ml Ionomycin and 50ng/ml PMA (Sigma) and Brefeldin A (BD bioscience) before flow cytometry stainingCX3CR1 + macrophages, CD103 + DC and ILC3 were pulsed overnight and 4h respectively with 10mg/ml OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] peptide (Anaspec) and co-culture 18hours with OTII Treg cells (refered to Figure 5 ). Intestinal CX3CR1 + macrophages were treated for 30min with 1.25mg of recombinant LAG-3 Fc (R&D systems) or IgG2a Fc (R&D systems) followed by a 2 hours stimulation with 100ng/ml of LPS (refered to Figure 7) . Histology from colon strips were fixed in 10% neutral buffered formalin overnight, transferred to 70% ethanol, processed routinely, embedded in paraffin, sectioned at 4-5 mm, then stained with hematoxylin and eosin. Tissues were scored for severity of disease by a pathologist in a blinded fashion according to three criterias: Inflammation: when present was characterized by infiltration with large numbers (60-70%) of mononuclear cells (macrophages and lymphocytes) and 30-40% of neutrophils and band cells. The scoring of inflammation includes severity of infiltration, loss of glands, erosion, dilatation of glandular lumina, presence of crypt abscess and degeneration of epithelial cells. Inflammation was scored on a scale of 0-4, 0 = negative; 1 = minimum, 2 = mild; 3 = moderate; 4 severe.Apoptosis: The prevalence of apoptotic bodies were scored on a scale of 0-3, 0 = negative; 1 = low, 2 = moderate; 3 = high.Regeneration: Regenerative changes assessed include scoring of the prevalence of mitotic figures in the upper 1/3 of the mucosa, nuclear density (nuclear crowding) within individual glandular structures, regularity of the surface epithelium. Apoptosis was scored on a scale of 0-3, 0 = negative; 1 = low, 2 = moderate; 3 = high.
Immunofluorence Formalin fixed paraffin embedded (FFPE) tissue sectioned at 4mm, then deparaffinized and rehydrated with serial passage through changes of xylene and graded ethanols. Slides were subjected to heat antigen retrieval in 1x Target Retrieval Solution, pH 6.1 (Dako). Tissues were blocked 1h with 1% BSA prior to an overnight incubation with primary antibody anti-CD3 (Dako) and anti-F4/80 (BM8, ebioscience). Slides were washed and incubated with anti-rabbit Alexa Fluor 488 and anti-rat Cy3 (Jackson Immunoresearch) for 1 hour. Stained slides were counterstained with DAPI (Fischer Scientist) and coverslipped for analysis. Fluorescence was visualized on the EVOS FL Cell Imaging System (Life Technologies).
In Situ Hybrization RNA in situ hybridization for murine Foxp3, Cx3cr1, and Il23r mRNA was performed manually using the RNAscopeÒ 2.5 HD Duplex Reagent Kit (Advanced Cell Diagnostics, Inc.) according to the manufacturer's instructions. Briefly, 5 mm formalin fixed, paraffin embedded (FFPE) tissue sections were pretreated with heat and protease prior to hybridization with the target oligonucleotide probes. Preamplifier, amplifier and HRP-AP-labeled oligos were then hybridized sequentially, followed by chromogenic precipitate development. Each sample was quality controlled for RNA integrity with a RNAscopeÒ probe specific to PPIB (C1)-Polr2a (C2) RNA and for background with a probe specific to bacterial DapB RNA. Specific RNA staining signal was identified as blue and magenta, punctate dots. Samples were counterstained with Gill's Hematoxylin.
ELISA and Luminex
Cell culture supernatants or serum cytokine concentration were measured using Luminex system (Millipore Corporation). Mouse IL-22, IL-1b, IL-23 and IL-10 ELISA (Quantikine kits) from R&D systems were used according to manufacturer's protocol. Supernatant were collected and spun at 6000 rpm for 15 min at 4 C. Clear supernatant was collected and stored at -80 C until ELISA analysis. DNase-treated total RNA was reverse-transcribed using QuantiTect Reverse Transcription (Qiagen, Valencia, CA) per manufacturer's instructions. Primers were obtained commercially from Thermo Fisher Scientific (Foster City, CA). Gene specific pre-amplification was done on at least 2 ng cDNA per Fluidigm BiomarkÒ manufacturer's instructions (Fluidigm, Foster City). Real-time quantitative PCR was then done on the Fluidigm BiomarkÒ using two unlabeled primers at 900 nM each and 250 nM of FAM-labeled probe (Thermo Fisher Scientific, Foster City, CA) with Taqman Universal PCR Master Mix containing UNG. Samples and primers were run on either a 48.48 array or 96.96 array per manufacturer's instructions (Fluidigm, Foster City). Ubiquitin expression were measured in a separate reaction and used to normalize the data by the DCt method. (Using the mean cycle threshold value for ubiquitin and the gene of interest for each sample, the equation 1.8^(Ct ubiquitin minus Ct gene of interest) x 10 4 was used to obtain the normalized values.). Primer sequences are available on demand. Preparation of FFPE RNA Tissue Lysates and Subsequent Gene-Expression Analysis using the NanoString nCounterÔ System RNA was isolated from slides of FFPE tissue for analysis on the NanoString nCounterÔ gene expression platform (NanoString Technologies, Seattle, WA). Prior to RNA isolation, tissue sections were deparaffinized in xylene for 3 x 5 min, then sequentially rehydrated in 100% ethanol for 2 x 2 min, 95% ethanol for 2 min, 70% ethanol for 2 min and then immersed in dH2O until ready to be processed. Tissue was lysed on the slide by adding 10-50ul of PKD buffer (Qiagen catalog #73504). Tissue was then scraped from the slide and transferred to a 1.5 ml eppendorf tube. Proteinase K (Roche Catalog #03115836001) was added at no more than 10% final volume and the RNA lysate was incubated for 15 min at 55 C and then 15 min at 80 C. RNA was isolated using Qiagen RNeasy FFPE kit per manufacturer's protocol (Qiagen, Valencia, CA). Sample concentration was measured on the NanoDrop Spectrophotometer (Thermo Fisher Scientific, Foster City, CA) per manufacturer protocol. The resulting total RNA was stored at -80 C until gene expression profiling was performed using the NanoString nCounterÔ system.
Per sample, 50ng of total RNA isolated from FFPE was mixed with a 3 0 biotinylated capture probe and a 5 0 reporter probe tagged with a fluorescent barcode, from a custom designed gene expression codeset. Probes and lysate were hybridized overnight at 65 C for 12-16 hours. Hybridized samples were then run on the NanoString preparation station using their high sensitivity protocol per manufacturer's instructions (NanoString Technologies, Seattle, WA). The samples were scanned at maximum scan resolution capabilities using the nCounterÔ Digital Analyzer (NanoString Technologies, Seattle, WA).
All sample and data normalization occurred within the nCounterÔ digital analyzer software, nSolverÔ. Specifically, the raw code count data was normalized using a positive control normalization factor based off the spiked-in positive control raw counts and also a content normalization factor derived from the raw counts of a set of relevant housekeeping genes. Transcripts with counts less than or equal to the highest embedded negative controls (background noise) in that sample are first set to its background. The gene count for each gene is then subtracted from this background so that each sample has the same footing where zero numbers represent undetectable noise.
Statistics
Unless mentioned otherwise two-tailed paired and unpaired t test were used to calculated statistical significance. P values <0.05 were considered significant. * P<0.05, ** P<0.01, *** P<0.001. Statistics were performed using GraphPad Prism 7 software.
